Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19 : A systematic review and meta-analysis
Copyright © 2022 The Author(s). Published by Elsevier GmbH.. All rights reserved..
BACKGROUND: Qingfei Paidu decoction (QFPDD) showed to be beneficial for the treatment of coronavirus disease 2019 (COVID-19) in China.
PURPOSE: This study aimed to systematically assemble the evidence on the efficacy and safety of QFPDD combined with Western medicine treatments (WMT) for COVID-19.
STUDY DESIGN: Systematic review and meta-analysis.
METHODS: A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, CNKI, CSTJ, CBM, Wanfang Data for clinical trials with a control arm until January 13, 2022. Studies matched the selection criteria were included. Data extraction and quality assessment of the included studies were independently conducted by two reviewers. Review Manager 5.4 was used for meta-analysis.
RESULTS: A total of 9 trials including 1108 COVID-19 patients met the selection criteria. Meta-analysis demonstrated that QFPDD combined with WMT reduced aggravation rate (AR) by 71% [risk ratio (RR) = 0.29, 95% confidence intervals (CI) (0.17, 0.51)], increased effective rate (ER) by 13% [RR = 1.13, 95%CI (1.04, 1.22)], shortened 4.78 days of viral shedding [95%CI (-5.79, -3.77)] and 4.45 days of hospital stay [95%CI (-6.05, -2.86)], also decreased the incidence of adverse events (AE) by 56% [RR = 0.44, 95%CI (0.22, 0.89)].
CONCLUSION: QFPDD combined with WMT might reduce the proportion of severe cases and the incidence of AE, shorten the duration of viral shedding and length of hospital stay. More randomized controlled trials (RCTs) are required to confirm our findings in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Phytomedicine : international journal of phytotherapy and phytopharmacology - 102(2022) vom: 20. Juli, Seite 154166 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Lei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.06.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phymed.2022.154166 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341584355 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341584355 | ||
| 003 | DE-627 | ||
| 005 | 20231226012122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phymed.2022.154166 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM341584355 | ||
| 035 | |a (NLM)35636170 | ||
| 035 | |a (PII)S0944-7113(22)00244-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Lei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19 |b A systematic review and meta-analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.06.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier GmbH.. All rights reserved. | ||
| 520 | |a BACKGROUND: Qingfei Paidu decoction (QFPDD) showed to be beneficial for the treatment of coronavirus disease 2019 (COVID-19) in China | ||
| 520 | |a PURPOSE: This study aimed to systematically assemble the evidence on the efficacy and safety of QFPDD combined with Western medicine treatments (WMT) for COVID-19 | ||
| 520 | |a STUDY DESIGN: Systematic review and meta-analysis | ||
| 520 | |a METHODS: A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, CNKI, CSTJ, CBM, Wanfang Data for clinical trials with a control arm until January 13, 2022. Studies matched the selection criteria were included. Data extraction and quality assessment of the included studies were independently conducted by two reviewers. Review Manager 5.4 was used for meta-analysis | ||
| 520 | |a RESULTS: A total of 9 trials including 1108 COVID-19 patients met the selection criteria. Meta-analysis demonstrated that QFPDD combined with WMT reduced aggravation rate (AR) by 71% [risk ratio (RR) = 0.29, 95% confidence intervals (CI) (0.17, 0.51)], increased effective rate (ER) by 13% [RR = 1.13, 95%CI (1.04, 1.22)], shortened 4.78 days of viral shedding [95%CI (-5.79, -3.77)] and 4.45 days of hospital stay [95%CI (-6.05, -2.86)], also decreased the incidence of adverse events (AE) by 56% [RR = 0.44, 95%CI (0.22, 0.89)] | ||
| 520 | |a CONCLUSION: QFPDD combined with WMT might reduce the proportion of severe cases and the incidence of AE, shorten the duration of viral shedding and length of hospital stay. More randomized controlled trials (RCTs) are required to confirm our findings in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical effect | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Qingfei Paidu decoction | |
| 650 | 4 | |a Systematic review | |
| 650 | 4 | |a Western medicine treatments | |
| 650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
| 650 | 7 | |a qingfei paidu decoction |2 NLM | |
| 700 | 1 | |a Ma, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Nannan |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Sihong |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Xinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Renbo |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Yipin |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Youwen |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Hongjie |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Guangkun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Huamin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yongyan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Phytomedicine : international journal of phytotherapy and phytopharmacology |d 1994 |g 102(2022) vom: 20. Juli, Seite 154166 |w (DE-627)NLM093820402 |x 1618-095X |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2022 |g day:20 |g month:07 |g pages:154166 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phymed.2022.154166 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2022 |b 20 |c 07 |h 154166 | ||